Erik Goluboff, MD, MBA, Tyra Biosciences, Inc.

Affiliations:

Tyra Biosciences, Inc.

Carlsbad, CA, USA

Articles by Erik Goluboff, MD, MBA, Tyra Biosciences, Inc.

Oral Selective FGFR3 Inhibition in Urothelial Carcinoma: Opportunities in Intermediate Risk Non-Muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma

ByErik Goluboff, MD, MBA, Tyra Biosciences, Inc.

March 30th 2026

Latest Updated Articles

Trending on Urology Times

European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC

FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC

Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC

ESMO 2026: Key presentations across genitourinary oncology

How PSMA-PET shapes staging and recurrence workup in prostate cancer